Earnings History Data for Recursion Pharmaceuticals, Inc. (RXRX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering. Recursion Pharmaceuticals Inc. is based in SALT LAKE CITY.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
06-11-2024	AH		RXRX	Recursion Pharmaceuticals, Inc.	1,870	-0.34	-0.33	-0.43	Recursion Pharmaceuticals EPS of -$0.34 misses by $0.01, revenue of $26.1M misses by $3.73M [11/6/2024 5:37 PM]	6.90	-0.07 (-1.07%)	6.88	-0.09 (-1.29%)	5.03 - 15.74	5,160,907	4,160,000	133,681
Recursion Pharmaceuticals EPS of -$0.34 misses by $0.01, revenue of $26.1M misses by $3.73M [11/6/2024 5:37 PM] Recursion Pharmaceuticals Inc (RXRX) Q3 2024 Earnings Report Preview: What To Expect [Nov-05-24 07:45AM] Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results [2024-11-06 04:15PM]
09-05-2024	AH		RXRX	Recursion Pharmaceuticals, Inc.	2,060	-0.39	-0.43	-0.34	Recursion Pharmaceuticals GAAP EPS of -$0.39 beats by $0.03, revenue of $13.79M beats by $0.72M [5/9/2024 5:05 PM]	8.62	-0.02 (-0.18%)	9.05	0.41 (4.75%)	4.92 - 16.75	6,318,890	3,810,000	83,506
Recursion Pharmaceuticals GAAP EPS of -$0.39 beats by $0.03, revenue of $13.79M beats by $0.72M [5/9/2024 5:05 PM] AI-discovered drugs have an 80%–90% success rate: study [5/10/2024 2:13 PM]
09-11-2023	PM		RXRX	Recursion Pharmaceuticals	1,317	-0.43	-0.38	0.00	Recursion Pharmaceuticals GAAP EPS of -$0.43 misses by $0.05, revenue of $10.53M misses by $2.34M [11/9/2023 8:14 AM]	5.24	-0.39 (-6.93%)	5.75	0.12 (2.13%)	4.54 - 16.75	3,190,792	3,840,000	40,907
Recursion Pharmaceuticals GAAP EPS of -$0.43 misses by $0.05, revenue of $10.53M misses by $2.34M [11/9/2023 8:14 AM]
08-05-2023	PM		RXRX	Recursion Pharmaceuticals	983.00	-0.34	-0.34	0.00	Recursion Pharmaceuticals GAAP EPS of -$0.34, revenue of $12.13M [5/8/2023 8:28 AM]	5.58	0.42 (8.24%)	5.31	0.15 (2.91%)	4.54 - 14.18	1,851,547	1,410,000	2,671
Recursion to buy two firms in AI-enabled drug discovery space [5/8/2023 8:28 AM] Recursion Pharmaceuticals GAAP EPS of -$0.34, revenue of $12.13M [5/8/2023 8:28 AM]
27-02-2023	AH		RXRX	Recursion Pharmaceuticals	1,488	-0.31	-0.15	0.00		8.11	0.39 (5.05%)	7.72	0.0 (0.00%)	4.92 - 14.18	1,006,356	800,000	31,282

08-11-2022	AH	4:15 PM ET (Nov 8)	RXRX	Recursion Pharmaceuticals	1,668	-0.35	-0.36	0.00	Recursion Pharmaceuticals GAAP EPS of -$0.35 beats by $0.01, revenue of $13.16M beats by $6.31M [11/8/2022 5:10 PM]	10.30	0.70 (7.27%)	9.60	0.0 (0.00%)	4.92 - 21.19	884,895	880,000	23,101
Recursion Pharmaceuticals GAAP EPS of -$0.35 beats by $0.01, revenue of $13.16M beats by $6.31M [11/8/2022 5:10 PM] Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results [Nov-08-22 04:30PM]
09-08-2022	AH	4:30 PM ET (Aug 9)	RXRX	Recursion Pharmaceuticals	1,692	-0.38	-0.35	0.00	Recursion Pharmaceuticals GAAP EPS of -$0.38, revenue of $7.67M [8/9/2022 5:23 PM]	9.86	1.05 (11.86%)	9.03	0.22 (2.50%)	4.92 - 29.40	1,235,961	680,000	400
Recursion Pharmaceuticals GAAP EPS of -$0.38, revenue of $7.67M [8/9/2022 5:23 PM]
10-05-2022	AH	After the close (May 10)	RXRX	Recursion Pharmaceuticals, Inc.	954.52	-0.33	0.51	-1.33	Recursion Pharmaceuticals GAAP EPS of -$0.33 misses by $0.84, revenue of $5.4M misses by $78.55M [5/10/2022 5:01 PM]	5.05	-0.64 (-11.25%)	5.50	-0.19 (-3.34%)	5.03 - 42.81	1,554,129	980,000	3,612
Recursion Pharmaceuticals GAAP EPS of -$0.33 misses by $0.84, revenue of $5.4M misses by $78.55M [5/10/2022 5:01 PM] Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates [May-10-22 07:05PM] Recursion Provides Business Updates and Reports First Quarter 2022 Financial Results [May-10-22 04:29PM]
10-11-2021	PM		RXRX	Recursion Pharmaceuticals	3,302	-0.28	-0.28	0.00	Recursion Pharmaceuticals EPS in-line, misses on revenue [11/10/2021 8:52 AM]	16.15	-3.45 (-17.63%)	0.0	0.0 (0.00%)	15.72 - 42.81	1,969,268	1,080,000	0
Recursion Pharmaceuticals EPS in-line, misses on revenue [11/10/2021 8:52 AM] Recursion Provides Business Updates and Reports Third Quarter 2021 Financials [Nov-10-21 07:55AM] Why Recursion Pharmaceuticals Stock Sank Today [Nov-10-21 04:39PM]
13-08-2021	PM		RXRX	Recursion Pharmaceuticals, Inc.	4,408	-0.31	-0.23	0.00	Recursion Pharmaceuticals EPS misses by $0.08, misses on revenue [8/13/2021 8:42 AM]	22.48	-0.51 (-2.21%)	23.10	0.11 (0.48%)	19.68 - 42.81	747,282	270,000	158
Recursion Pharmaceuticals EPS misses by $0.08, misses on revenue [8/13/2021 8:42 AM] Recursion Reports Second Quarter 2021 Financials and Provides Business Updates [Aug-13-21 07:55AM]